期刊
EXPERIMENTAL BIOLOGY AND MEDICINE
卷 233, 期 12, 页码 1498-1503出版社
SAGE PUBLICATIONS LTD
DOI: 10.3181/0806-S-207
关键词
pharmacogenomics; federal regulation; Food and Drug Administration
This article discusses the current ambiguous state of federal regulatory agency control over pharmacogenomic testing, a subset of genetic testing that combines information about genetic variability with pharmacology in order to improve drug recommendations. An analysis of the common three terms used to evaluate regulation of pharmacogenomic testing: research validity, clinical validity, and clinical utility, followed by a case study involving U. S. Food and Drug Administration (FDA) regulation of laboratory developed tests, illustrates the present gap in pharmacogenomic oversight. The existing agency overlap in regulating pharmacogenomic testing leads to unclear or even contradictory authoritative advice. Exp Biol Med 233:1498-1503,2008
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据